Noncardiac Chest Pain and Hypertensive Urgency During Long-term Intravenous Racemic Ketamine for Treatment-Resistant Depression.
作者信息
Patarroyo-Rodriguez Liliana, Vande Voort Jennifer L, Kung Simon, Brown Sarah K, Cavalcanti Stefanie, Ritter Matthew J, Singh Balwinder
出版信息
J Clin Psychopharmacol. 2025;45(1):49-52. doi: 10.1097/JCP.0000000000001939. Epub 2024 Nov 18.
Abstract
摘要
相似文献
1
Noncardiac Chest Pain and Hypertensive Urgency During Long-term Intravenous Racemic Ketamine for Treatment-Resistant Depression.长期静脉输注消旋氯胺酮治疗难治性抑郁症期间的非心源性胸痛和高血压急症
J Clin Psychopharmacol. 2025;45(1):49-52. doi: 10.1097/JCP.0000000000001939. Epub 2024 Nov 18.
2
Comparative efficacy, tolerability and acceptability of intravenous racemic ketamine with intranasal esketamine, aripiprazole and lithium as augmentative treatments for treatment-resistant unipolar depression: A systematic review and network meta-analysis.静脉注射消旋氯胺酮与鼻腔内依他佐辛、阿立哌唑和锂盐作为增效治疗难治性单相抑郁的疗效、耐受性和可接受性比较：系统评价和网络荟萃分析。
J Affect Disord. 2024 Feb 1;346:49-56. doi: 10.1016/j.jad.2023.11.023. Epub 2023 Nov 8.
3
Intravenous ketamine for depression: A clinical discussion reconsidering best practices in acute hypertension management.静脉注射氯胺酮治疗抑郁症：关于重新审视急性高血压管理最佳实践的临床讨论
Front Psychiatry. 2022 Sep 29;13:1017504. doi: 10.3389/fpsyt.2022.1017504. eCollection 2022.
4
How the Food and Drug Administration Drug Approval Process Relates to the Potential Approval of Intravenous Racemic Ketamine for Treatment-resistant Major Depression.食品和药物管理局的药物审批流程如何与静脉注射消旋氯胺酮治疗难治性重度抑郁症的潜在批准相关。
J Psychiatr Pract. 2024 Mar 1;30(2):134-138. doi: 10.1097/PRA.0000000000000768.
5
Long-term safety of ketamine and esketamine in treatment of depression.氯胺酮和艾司氯胺酮治疗抑郁症的长期安全性。
Expert Opin Drug Saf. 2022 Jun;21(6):777-787. doi: 10.1080/14740338.2022.2066651. Epub 2022 Apr 19.
6
Switching to Intranasal Esketamine Maintains the Antidepressant Response to Intravenous Racemic Ketamine Administration: A Case Series of 10 Patients.转为鼻内依他佐辛维持静脉注射消旋酮对抑郁症患者的治疗效果：10 例病例系列研究。
J Clin Psychopharmacol. 2021;41(5):594-599. doi: 10.1097/JCP.0000000000001456.
7
Intranasal racemic ketamine maintenance therapy for patients with treatment-resistant depression: a naturalistic feasibility study.鼻内消旋氯胺酮维持治疗难治性抑郁症患者：一项自然主义可行性研究。
BMC Psychiatry. 2025 Jan 7;25(1):23. doi: 10.1186/s12888-024-06448-x.
8
Intranasal racemic ketamine for patients hospitalized with treatment-resistant depression: A retrospective analysis.鼻腔内使用消旋体氯胺酮治疗治疗抵抗性抑郁症患者的回顾性分析。
Exp Clin Psychopharmacol. 2023 Jun;31(3):593-598. doi: 10.1037/pha0000627. Epub 2022 Dec 8.
9
Response to intravenous racemic ketamine after switch from intranasal (S)-ketamine on symptoms of treatment-resistant depression and post-traumatic stress disorder in Veterans: A retrospective case series.静脉注射消旋氯胺酮治疗退伍军人治疗抵抗性抑郁症和创伤后应激障碍症状：一项回顾性病例系列研究。
在鼻腔内给予 (S)-氯胺酮后转换为静脉注射消旋氯胺酮治疗的反应。
Pharmacotherapy. 2022 Mar;42(3):272-279. doi: 10.1002/phar.2664. Epub 2022 Feb 24.
10
Intravenous ketamine for treatment-resistant depression patients who have failed to respond to transcranial magnetic stimulation: A case series.经颅磁刺激治疗抵抗的抑郁患者静脉用氯胺酮治疗：一项病例系列研究。
J Affect Disord. 2023 Jul 15;333:18-20. doi: 10.1016/j.jad.2023.04.019. Epub 2023 Apr 17.
本文引用的文献
1
Ketamine and Esketamine for Depression in Daily Practice: Opportunities and Challenges.氯胺酮和艾司氯胺酮在日常临床中治疗抑郁症：机遇与挑战
J Clin Psychopharmacol. 2024;44(5):451-455. doi: 10.1097/JCP.0000000000001898. Epub 2024 Aug 22.
2
Blood pressure changes during ketamine infusion for the treatment of depression.氯胺酮输注治疗抑郁症过程中的血压变化。
Gen Hosp Psychiatry. 2024 Sep-Oct;90:62-67. doi: 10.1016/j.genhosppsych.2024.07.001. Epub 2024 Jul 4.
3
Ketamine Induced Acute Systolic Heart Failure.氯胺酮诱发的急性收缩性心力衰竭。
Eur J Case Rep Intern Med. 2024 Apr 23;11(6):004470. doi: 10.12890/2024_004470. eCollection 2024.
4
Efficacy of intravenous ketamine and intranasal esketamine with dose escalation for Major depression: A systematic review and meta-analysis.静脉注射氯胺酮和鼻内依他佐辛递增剂量治疗重度抑郁症的疗效：系统评价和荟萃分析。
J Affect Disord. 2024 Jul 1;356:379-384. doi: 10.1016/j.jad.2024.03.137. Epub 2024 Mar 26.
5
Change in neurocognitive functioning in patients with treatment-resistant depression with serial intravenous ketamine infusions: The Bio-K multicenter trial.难治性抑郁症患者连续静脉输注氯胺酮后神经认知功能的变化：Bio-K多中心试验。
Psychiatry Res. 2024 May;335:115829. doi: 10.1016/j.psychres.2024.115829. Epub 2024 Feb 28.
6
Ketamine's love story with the heart: A Takotsubo twist.氯胺酮与心脏的“爱情故事”：应激性心肌病的新情况
Am J Emerg Med. 2024 Mar;77:232.e5-232.e7. doi: 10.1016/j.ajem.2023.12.041. Epub 2024 Jan 3.
7
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.司美格鲁肽在肥胖但无糖尿病患者中的心血管结局。
N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11.
8
The Effect of Semaglutide on Blood Pressure in Patients without Diabetes: A Systematic Review and Meta-Analysis.司美格鲁肽对非糖尿病患者血压的影响：一项系统评价和荟萃分析
J Clin Med. 2023 Jan 18;12(3):772. doi: 10.3390/jcm12030772.
9
Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression: An Observational Study.静脉注射氯胺酮与鼻内艾司氯胺酮在难治性抑郁症患者临床实践中的比较疗效：一项观察性研究。
J Clin Psychiatry. 2023 Feb 1;84(2):22m14548. doi: 10.4088/JCP.22m14548.
10
Intravenous ketamine for depression: A clinical discussion reconsidering best practices in acute hypertension management.静脉注射氯胺酮治疗抑郁症：关于重新审视急性高血压管理最佳实践的临床讨论
Front Psychiatry. 2022 Sep 29;13:1017504. doi: 10.3389/fpsyt.2022.1017504. eCollection 2022.
Zotero 插件